| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YM-155 | GDSC1000 | pan-cancer | AAC | 0.072 | 0.04 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.076 | 0.04 |
| mRNA | Bosutinib | GDSC1000 | pan-cancer | AAC | 0.071 | 0.05 |
| mRNA | CHIR-99021 | CTRPv2 | pan-cancer | AAC | -0.072 | 0.05 |
| mRNA | CAY10603 | GDSC1000 | pan-cancer | AAC | -0.064 | 0.05 |
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | -0.078 | 0.05 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | -0.078 | 0.05 |
| mRNA | CHIR-99021 | GDSC1000 | pan-cancer | AAC | 0.066 | 0.05 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | 0.069 | 0.05 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | -0.075 | 0.05 |